XCY Stock Overview
A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$1.59 |
| 52 Week Low | US$0.76 |
| Beta | 1.65 |
| 11 Month Change | 10.39% |
| 3 Month Change | 0.97% |
| 1 Year Change | n/a |
| 33 Year Change | -60.39% |
| 5 Year Change | 1.28% |
| Change since IPO | -7.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| XCY | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 12.0% | 1.1% | 0.2% |
| 1Y | n/a | 16.5% | 8.5% |
Return vs Industry: Insufficient data to determine how XCY performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how XCY performed against the German Market.
Price Volatility
| XCY volatility | |
|---|---|
| XCY Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: XCY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine XCY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3,930 | Phil Frost | www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
| XCY fundamental statistics | |
|---|---|
| Market cap | €1.03b |
| Earnings (TTM) | -€127.64m |
| Revenue (TTM) | €678.97m |
1.5x
P/S Ratio-8.1x
P/E RatioIs XCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XCY income statement (TTM) | |
|---|---|
| Revenue | US$711.41m |
| Cost of Revenue | US$627.03m |
| Gross Profit | US$84.38m |
| Other Expenses | US$218.11m |
| Earnings | -US$133.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 11.86% |
| Net Profit Margin | -18.80% |
| Debt/Equity Ratio | 31.4% |
How did XCY perform over the long term?
See historical performance and comparison